Literature DB >> 28761390

Intensity-modulated radiation therapy for small cell carcinoma of the prostate: A case report.

Yaichiro Hashimoto1, Yuka Ishii1, Sawa Kono1, Sachiko Izumi1, Junpei Iizuka2, Atsuko Hiroi3, Kumiko Karasawa1.   

Abstract

Small cell carcinomas (SCC) make up only 1% of malignancies of the prostate. Reports of several case series have described outcomes of surgery and chemotherapy for SCC of the prostate, but few reports address radiotherapy. We treated a case of SCC of the prostate with intensity-modulated radiation therapy (IMRT) consisting of 70 Gy administered in 35 fractions followed by hormonal therapy using only luteinizing hormone-releasing hormone (LH-RH) agonist. The tumor volume decreased remarkably by 4 months after IMRT. The rapid decrease in tumor size of this SCC of the prostate seemed to suggest a similar high radiosensitivity to that of SCC of the lung, but the tumor increased rapidly thereafter within the radiation fields, and pelvic lymph node metastases had developed by 24 months after IMRT. By 28 months after IMRT, multiple lung metastases developed, and the patient died of SCC of the prostate 31 months after initial diagnosis.

Entities:  

Keywords:  IMRT; Prostate cancer; Radiotherapy; Small cell carcinoma

Year:  2017        PMID: 28761390      PMCID: PMC5524305          DOI: 10.1016/j.rpor.2017.06.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  11 in total

1.  Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study.

Authors:  Sundeep Deorah; Marepalli B Rao; Rachna Raman; Krishnanath Gaitonde; James F Donovan
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

2.  Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases.

Authors:  B Têtu; J Y Ro; A G Ayala; D E Johnson; C J Logothetis; N G Ordonez
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

Review 3.  Neuroendocrine differentiation in prostatic malignancy.

Authors:  P A di Sant'Agnese; A T Cockett
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

4.  Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

Authors:  A Fléchon; D Pouessel; C Ferlay; D Perol; P Beuzeboc; G Gravis; F Joly; S Oudard; G Deplanque; S Zanetta; P Fargeot; F Priou; J P Droz; S Culine
Journal:  Ann Oncol       Date:  2011-03-24       Impact factor: 32.976

Review 5.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

Review 6.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Authors:  Gustavo Arruda Viani; Eduardo Jose Stefano; Sergio Luis Afonso
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

7.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Authors:  Christos N Papandreou; Danai D Daliani; Peter F Thall; Shi-Ming Tu; Xuemei Wang; Adriana Reyes; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

8.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Authors:  Colleen A Lawton; Michelle DeSilvio; Mack Roach; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; Stephen Hahn; Charles R Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

9.  Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

Authors:  Stéphane Culine; Mounira El Demery; Pierre-Jean Lamy; François Iborra; Christophe Avancès; Frédéric Pinguet
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

Review 10.  Small cell carcinoma of the prostate.

Authors:  Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

View more
  1 in total

1.  Amrubicin is effective against small cell carcinoma of the prostate as a second-line chemotherapeutic agent: A case report.

Authors:  Fumisato Maesaka; Yasushi Nakai; Mitsuru Tomizawa; Takuya Owari; Makito Miyake; Takeshi Inoue; Satoshi Anai; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  IJU Case Rep       Date:  2019-03-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.